WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

(51) International Patent Classification 7: G01N 33/50, C12N 5/10, C12Q 1/68	A1	(11) International Publication Number: (43) International Publication Date:	WO 00/28323
(21) International Application Number: PCT/GB99/03648 (22) International Filing Date: 4 November 1999 (04.11.99)		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,	
(30) Priority Data: 9824501.2 10 November 1998 (10.11.98) (71) Applicant (for all designated States except US): Z LIMITED [GB/GB]; 15 Stanhope Gate, London W (GB)	ENEC		
(72) Inventors; and (75) Inventors/Applicants (for US only): GREEN, Isabelle [FR/G/B]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB), CHARLES, Andrew, David [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		5,	
(74) Agent: BILL, Kevin; AstraZeneca PLC, Global Inte Property, Mereside, Alderley Park, Macclesfield, C SK10 4TG (GB).			

(57) Abstract

An endogenous human protein designated BS69 is identified as a new modulator of the Transforming Growth Factor- β (TGF- β) cell signalling pathway. Methods are provided to identify compounds that interfere with the biological activity of BS69 on the TGF- β cell signalling pathway. Such compounds have potential as therapeutic agents.